Reckitt Benckiser Group announced today that it is expanding its U.S. manufacturing footprint by acquiring a 310,000 ft² pharmaceutical site in Wilson, North Carolina. The Slough, U.K.–based company said it will invest £155 million ($200 million) to establish a manufacturing facility in Wilson to produce Mucinex tablets and liquids to meet increased U.S. demand. Reckitt…

Sanofi recently announced that it is investing €40 million in its Lyon Gerland bioproduction site as it seeks to bolster its position in the immunology space. The investment will support production in France of the transplant drug Thymoglubulin, including €25 million toward developing and manufacturing a second-generation version of the drug. The remaining €15 million…

Otsuka Holdings will pay ICU Medical (Nasdaq: ICUI) an upfront payment of $200 million as part of a joint venture to enter the U.S. IV products market, which has been facing hurricane-related shortages this fall. The partnership — which involves  ICU Medical providing commercial services for Otsuka’s Otsuka Pharmaceutical Factory (OPF) subsidiary — also includes…

Baxter recently stopped selling IV products in China as it continues its efforts to address hurricane-related supply shortages in the U.S. In a statement shared with Pharmaceutical Processing World, the Deerfield, Illinois–based company said: “After careful consideration, and given the numerous alternative IV solution suppliers that exist in the Chinese market, Baxter has suspended commercial…

MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…

BD (NYSE:BDX) announced today that it entered into a collaboration with ten23 health to develop a new way to track prefillable syringes (PFS). ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute to the product offering. It recently entered into a production collaboration with on-body drug delivery device maker…

Johnson & Johnson recently announced plans to invest more than $2 billion in a new manufacturing facility in North Carolina. The company plans to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina, to expand the production of its pipeline of innovative biologics. The expansion supports J&J’s broader plan to advance more than 70…

SK Pharmteco announced that it expanded its small molecule and peptide production capabilities with a $260 million investment. The Rancho Cordova, California-based CDMO plans to construct a new state-of-the-art facility in Sejong, South Korea. It expects to begin operations at the new plant — the company’s fifth in South Korea — in late 2026. The…

PCI Pharma Services announced that it’s investing more than $365 million in infrastructure to support assembly and packaging efforts. The investment supports the clinical- and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. PCI Pharma plans to put its investment toward new and…

Curium announced today that it opened a new facility in Petten, The Netherlands, to produce non-carrier added lutetium-177 (Lu-177). The Paris-based company expanded its capacity to meet the growing global demand for Lu-177 for the treatment of cancer patients. Using in-licensed technology from Turkey-based Eczacıbaşı-Monrol, the facility will initially include two production lines. Curium also…